Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Pressler, T ^a   Bohmova, C ^b   Conway, S ^c   Dumcius, S ^d   Hjelte, L ^e   Hoiby N ^a   Kollberg, H ^f   Tummler B ^g   Vavrova, V ^b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d VILNIUS UNIVERSITY   (Lithuania)

^e Karolinska Stockholm CF Centre   (Sweden)

^f Uppsala CF Center   (Sweden)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic infection; Cystic fibrosis; Definitions; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G ANTIBODY;

AGE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFECTION CONTROL; INTENSIVE CARE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE;

CHRONIC DISEASE; CYSTIC FIBROSIS; EUROPE; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79958089335     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60011-8     Document Type: Article

References (24)

1. Frederiksen B, Lanng S, Koch C, Hoiby N Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996, 21(3):153-158.
2. Hoiby N Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977, 262:1-96.
3. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
4. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16(4):749-767.
5. Frederiksen B, Koch C, Hoiby N Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999, 28(3):159-166.
6. Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001, 31(1):1-12.
7. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32(4):277-287.
8. Schiotz PO, Hoiby N, Juhl F, Permin H, Nielsen H, Svehag SE Immune complexes in cystic fibrosis. Acta Pathol Microbiol Scand C 1977, 85(1):57-64.
9. Kerem E, Corey M, Gold R, Levison H Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990, 116(5):714-719.
10. Henry RL, Mellis CM, Petrovic L Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12(3):158-161.
11. Ballmann M, Rabsch P, von der Hardt H Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998, 53(9):732-737.
12. Lee TW, Brownlee KG, Conway SP, Dentón M, Littlewood JM Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
13. Proesmans M, Balinska-Miskiewicz W, Dupont L, et al. Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 2006, 27(5):937-943.
14. Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Hoiby N Early rise of anti-pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - a case control study. J Cyst Fibros 2006, 5(1):9-15.
15. Pressler T, Karpati F, Granstrom M, et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009, 8(1):37-42.
16. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007, 42(3):249-255.
17. Pseudomonas aeruginosa infection: prevention and infection control. Report of the United Kingdom Cystic Fibrosis Trust's Infection Control Group. 2001.
18. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28(5):321-328.
19. Lee TW, Brownlee KG, Dentón M, Littlewood JM, Conway SP Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004, 37(2):104-110.
20. Lebecque P, Leal T, Zylberberg K, Reychler G, Bossuyt X, Godding V Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2006, 5(4):237-244.
21. Knudsen PK, Olesen HV, Hoiby N, et al. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. J Cyst Fibros 2009, 8(2):135-142.
22. Hansen CR, Pressler T, Hoiby N Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008, 7(6):523-530.
23. Frederiksen B, Koch C, Hoiby N Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23(5):330-335.
24. Kappler M, Kraxner A, Reinhardt D, Ganster B, Griese M, Lang T Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006, 61(8):684-688.